WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 412177

CAS#: 129026-48-8

Description: 502U83 is an arylmethylaminopropanediol that displays significant antitumor activity in a number of murine and human tumor-model systems

Chemical Structure

CAS# 129026-48-8

Theoretical Analysis

MedKoo Cat#: 412177
Name: 502U83
CAS#: 129026-48-8
Chemical Formula: C21H25NO4
Exact Mass: 355.1784
Molecular Weight: 355.43
Elemental Analysis: C, 70.96; H, 7.09; N, 3.94; O, 18.01

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: 502U83; BW502U83; BW-502U83 BW 502U83

IUPAC/Chemical Name: 1,3-Propanediol, 2-(((10-(2-hydroxyethoxy)-9-anthracenyl)methyl)amino)-2-methyl-

InChi Key: InChI=1S/C21H25NO4/c1-21(13-24,14-25)22-12-19-15-6-2-4-8-17(15)20(26-11-10-23)18-9-5-3-7-16(18)19/h2-9,22-25H,10-14H2,1H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 355.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Dorr RT, Bellamy W, Liddil JD, Baker A, Bair KW. Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. PMID: 9807165.

2: van der Graaf WT, Zijlstra JG, de Vries EG, Nethersell AB, Mulder NH. In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol. Anticancer Drugs. 1995 Feb;6(1):34-9. doi: 10.1097/00001813-199502000-00003. PMID: 7756681.

3: Schilsky RL, Ratain MJ, Janisch L, Vogelzang NJ, Lucas VS, Ravitch J, Hohneker JA, Clendeninn NJ, Tuttle RL. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993;31(4):283-8. doi: 10.1007/BF00685672. PMID: 8422691.

4: Patel DK, Lewis RP, Hinton ML, Schroeder DH, Shockcor JP, Johnson RL, Sigel CW. Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70. PMID: 8095228.

5: Lam KS, Alberts DS, Peng YM, Brodar F, Matias B, Modiano M, Tuttle R, Sol Lucas V, Wargin W. Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients. Anticancer Drugs. 1992 Jun;3(3):219-24. doi: 10.1097/00001813-199206000-00003. PMID: 1525401.

6: Bair KW, Andrews CW, Tuttle RL, Knick VC, Cory M, McKee DD. 2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding. J Med Chem. 1991 Jul;34(7):1983-90. doi: 10.1021/jm00111a010. PMID: 2066971.

7: Carter CA, Bair KW. Effects of isomeric 2-(arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells. Invest New Drugs. 1991 May;9(2):125-36. doi: 10.1007/BF00175080. PMID: 1874597.

8: Von Hoff DD, Kuhn JG, Havlin KA, Langevin AM, Brown TD, Weiss GR, Turner JN, Purvis J, Lucas VS, Bair KW, et al. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule. Cancer Res. 1990 Dec 1;50(23):7496-500. PMID: 2253197.

9: Bair KW, Tuttle RL, Knick VC, Cory M, McKee DD. (1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies. J Med Chem. 1990 Sep;33(9):2385-93. doi: 10.1021/jm00171a012. PMID: 2391683.